RBC Life Sciences, Inc. (RBCL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RBC Life Sciences, Inc. (RBCL) trades at $0.00 with AI Score 48/100 (Grade C). RBC Life Sciences, Inc. develops, manufactures, and distributes nutritional supplements and personal care products. Market cap: $1,549, Sector: Consumer defensive.
Last analyzed: Mar 17, 2026Analyst Coverage for RBCL: RBCL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RBCL against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RBCL: the 1 perspectives are evenly split.
RBC Life Sciences, Inc. (RBCL) Consumer Business Overview
RBC Life Sciences, Inc. formulates and distributes nutritional supplements and personal care items, leveraging a network of independent distributors across North America, Southeast Asia, and Australia. With a focus on both nutritional and medical product segments, the company addresses diverse consumer health and wellness needs.
What Is the Investment Thesis for RBCL?
Investing in RBC Life Sciences, Inc. requires careful consideration of its financial standing and market position. With a market capitalization of $0.00 billion and a negative P/E ratio, the company's profitability is a concern, highlighted by a negative profit margin of -2.9%. The company's gross margin stands at 52.8%. Growth catalysts include potential expansion within the nutritional supplements market and strategic partnerships to broaden distribution. However, the company faces risks related to competition, regulatory changes, and reliance on its network of independent distributors. The beta of -12.32 suggests a high level of volatility relative to the market.
Based on FMP financials and quantitative analysis
RBCL Key Highlights
- Gross Margin of 52.8% indicates a solid ability to control production costs within the Nutritional Products segment.
- Negative Profit Margin of -2.9% reflects ongoing challenges in achieving overall profitability.
- Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity.
- Beta of -12.32 suggests the stock price is highly volatile and moves inversely to the market.
- The company operates in North America, Southeast Asia, and Australia, providing geographic diversification.
Who Are RBCL's Competitors?
RBCL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FACYF Fancl Corporation | $17.45 | +0.00% | $2.37B | 63 |
| SGI Somnigroup International Inc | $72.67 | +0.48% | $15.28B | 62 |
| ELF e.l.f. Beauty, Inc. | $61.15 | +0.77% | 4B | 59 |
| MIOFF Milbon Co., Ltd. | $52.60 | +0.00% | $1.71B | 58 |
| KCDMF Kimberly-Clark de México, S. A. B. de C. V. | $2.10 | -3.67% | $6.30B | 48 |
| KCDMY Kimberly-Clark de México, S. A. B. de C. V. | $10.66 | +4.00% | $6.41B | 48 |
| PG The Procter & Gamble Company | $149.61 | +0.86% | $348.38B | 48 |
| RAY Raytech Holding Limited Ordinary Shares (RAY) | $3.13 | -0.16% | $9.30M | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RBCL's Key Strengths?
- Diversified product portfolio including nutritional supplements and medical products.
- Established distribution network across multiple geographic regions.
- Proprietary formulations for certain products.
- MPM Medical brand recognition in the wound care market.
What Are RBCL's Weaknesses?
- Negative profit margin indicating profitability challenges.
- Limited market capitalization and liquidity.
- Reliance on independent distributors.
- High beta suggesting significant stock price volatility.
What Could Drive RBCL Stock Higher?
- Potential expansion into new international markets, driving revenue growth.
- Increasing demand for nutritional supplements and personal care products.
- Strategic partnerships to expand distribution network.
- Launch of new and innovative products in the wound care segment.
What Are the Key Risks for RBCL?
- Intense competition from larger and more established companies.
- Changing consumer preferences and trends impacting product demand.
- Regulatory changes and compliance requirements increasing costs.
- Negative profit margin indicating profitability challenges.
- Limited market capitalization and liquidity.
What Are the Growth Opportunities for RBCL?
- Expansion in Southeast Asia: RBC Life Sciences can capitalize on the growing demand for nutritional supplements and personal care products in Southeast Asian markets. The region's expanding middle class and increasing health awareness present a significant opportunity. Strategic partnerships with local distributors and targeted marketing campaigns can drive market penetration. The Southeast Asian nutraceuticals market is projected to reach $40 billion by 2028, offering substantial growth potential.
- Product Innovation in Medical Products: The company can invest in research and development to expand its portfolio of wound care products. Focusing on innovative solutions, such as advanced wound dressings and antimicrobial technologies, can attract new customers and increase market share. The global advanced wound care market is expected to reach $22 billion by 2027, driven by an aging population and increasing prevalence of chronic wounds.
- E-commerce and Direct-to-Consumer Sales: RBC Life Sciences can enhance its online presence and expand its direct-to-consumer sales channels. Investing in a user-friendly e-commerce platform and digital marketing strategies can reach a broader customer base and improve sales efficiency. The global e-commerce market for health and personal care products is experiencing rapid growth, providing a significant opportunity for the company.
- Strategic Partnerships and Acquisitions: The company can pursue strategic partnerships and acquisitions to expand its product portfolio and geographic reach. Collaborating with complementary businesses or acquiring companies with innovative technologies can accelerate growth and enhance competitiveness. Identifying potential targets and conducting thorough due diligence are crucial for successful partnerships and acquisitions.
- Focus on Personalized Nutrition: RBC Life Sciences can leverage advancements in personalized nutrition to develop customized supplement programs tailored to individual needs. By incorporating genetic testing and data analytics, the company can offer targeted solutions that address specific health concerns. The personalized nutrition market is expected to grow significantly, driven by increasing consumer interest in personalized health and wellness.
What Opportunities Does RBCL Have?
- Expansion in emerging markets with growing demand for health and wellness products.
- Development of new and innovative products to address evolving consumer needs.
- Strategic partnerships and acquisitions to expand market reach and product offerings.
- Increased focus on e-commerce and direct-to-consumer sales.
What Threats Does RBCL Face?
- Intense competition from larger and more established companies.
- Changing consumer preferences and trends.
- Regulatory changes and compliance requirements.
- Economic downturns affecting consumer spending.
What Are RBCL's Competitive Advantages?
- Established distribution network in North America, Southeast Asia, and Australia.
- Diversified product portfolio across nutritional supplements, personal care, and medical products.
- MPM Medical brand recognition in the wound care market.
What Does RBCL Do?
Founded in 1988 and headquartered in Irving, Texas, RBC Life Sciences, Inc. operates within the consumer defensive sector, specifically focusing on household and personal products. The company manufactures, markets, and distributes a range of nutritional supplements and personal care products. RBC Life Sciences operates through two primary segments: Nutritional Products and Medical Products. The Nutritional Products segment offers a variety of supplements, including herbs, vitamins, and minerals, as well as natural skin, hair, and body care products. Key products include Stem-Kine, Microhydrin antioxidants, VitAloe, OliViva, Organic Spirulina, and NeuroBright. The segment also features products like Colo-Vada Plus, HydraCel, 24 Seven, Immune 360, and Aloe Gelee. The Medical Products segment focuses on wound care products, including cleansers, dressings, hydrogels, collagen, calcium alginates, moisture barriers, and antimicrobials. These products are marketed under the MPM Medical brand to hospitals, nursing homes, clinics, and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors. The company's geographic reach extends across North America, Southeast Asia, and Australia, utilizing a network of independent distributors and license arrangements to reach its customer base.
What Products and Services Does RBCL Offer?
- Manufactures and distributes nutritional supplements.
- Offers personal care products.
- Provides wound care products for medical applications.
- Markets products in North America, Southeast Asia, and Australia.
- Operates through a network of independent distributors.
- Sells medical products under the MPM Medical brand.
How Does RBCL Make Money?
- Develops and manufactures nutritional supplements and personal care products.
- Distributes products through a network of independent distributors and license arrangements.
- Sells medical products to hospitals, nursing homes, clinics, and pharmacies through medical/surgical supply dealers and pharmaceutical distributors.
What Industry Does RBCL Operate In?
RBC Life Sciences, Inc. operates in the competitive household and personal products industry, which is characterized by evolving consumer preferences and increasing demand for natural and organic products. The global nutritional supplements market is expected to continue growing, driven by rising health awareness and an aging population. Key competitors include companies like ANFIF (Anfield Capital Management Inc.) and CFPI (California Products Corporation). RBC Life Sciences differentiates itself through its focus on both nutritional and medical products, offering a diversified portfolio to address various health and wellness needs.
Who Are RBCL's Key Customers?
- Individual consumers seeking nutritional supplements and personal care products.
- Hospitals and nursing homes requiring wound care products.
- Clinics and pharmacies offering medical products.
RBCL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future prospects, suggesting that management believes in upcoming growth.
- Community sentiment has shifted positively, with discussions highlighting the potential of RBC Life Sciences' innovative products.
- Market perception has improved due to recent partnerships that could enhance distribution and visibility in the healthcare sector.
- Analysts have noted increased interest in the biotech space, which could lead to a favorable environment for companies like RBC Life Sciences.
Bear Case
- Concerns about regulatory hurdles in the biotech industry have led some investors to question the viability of RBC Life Sciences' product pipeline.
- Recent social media sentiment reflects skepticism regarding the company's ability to compete with larger, established players in the market.
- There are lingering uncertainties regarding the overall economic environment, which could impact funding and investment in biotech firms like RBC Life Sciences.
- Some community members express caution due to the company's historical performance, suggesting that past challenges may resurface.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RBCL Latest News
-
Head-To-Head Analysis: Senestech (NASDAQ:SNES) vs. RBC Life Sciences (OTCMKTS:RBCL)
defenseworld.net · Apr 14, 2026
RBCL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RBCL.
Price Targets
Wall Street price target analysis for RBCL.
RBCL MoonshotScore
What does this score mean?
The MoonshotScore rates RBCL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Price
CEO
David Price serves as the CEO of RBC Life Sciences, Inc., overseeing the company's strategic direction and operations. His background includes experience in the health and wellness industry, with a focus on nutritional supplements and personal care products. He has been involved in various leadership roles, contributing to the company's growth and expansion. Price's expertise lies in product development, marketing, and distribution, with a strong emphasis on building and maintaining relationships with independent distributors.
Track Record: Under David Price's leadership, RBC Life Sciences has focused on expanding its product portfolio and strengthening its distribution network. He has overseen the launch of new products and initiatives to enhance the company's market presence. Key milestones include expanding the company's reach in Southeast Asia and developing strategic partnerships to drive growth. His tenure has been marked by efforts to improve operational efficiency and enhance shareholder value.
RBCL OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RBC Life Sciences, Inc. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks face fewer regulatory requirements and may carry higher risks due to the lack of transparency and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's financial statements and disclosures.
- Research the company's management team and track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any news or reports of fraud or misconduct.
- Company has been in business since 1988.
- Operates in multiple geographic regions.
- Offers a diversified product portfolio.
- Has a network of independent distributors.
- Sells medical products under the MPM Medical brand.
What Investors Ask About RBC Life Sciences, Inc. (RBCL) — Consumer Defensive
What does RBC Life Sciences, Inc. do?
RBC Life Sciences, Inc. is a manufacturer and distributor of nutritional supplements, personal care products, and medical products. Operating through two segments, Nutritional Products and Medical Products, the company offers a range of products including vitamins, minerals, skin care items, and wound care solutions. These products are sold across North America, Southeast Asia, and Australia through a network of independent distributors and medical supply dealers. The company aims to address consumer health and wellness needs through its diverse product portfolio.
What do analysts say about RBCL stock?
Currently, there is no readily available analyst coverage or consensus on RBC Life Sciences, Inc. (RBCL) due to its OTC market listing and limited market capitalization. Investors should conduct their own thorough research and due diligence before making any investment decisions. Key valuation metrics, such as P/E ratio and profit margin, should be carefully analyzed in the context of the company's industry and competitive landscape.
What are the main risks for RBCL?
RBC Life Sciences, Inc. faces several risks, including intense competition in the nutritional supplement and personal care markets, changing consumer preferences, and regulatory challenges. The company's negative profit margin and limited liquidity pose financial risks. Additionally, its reliance on independent distributors and its OTC market listing add further layers of risk. Investors should carefully consider these factors before investing in RBCL.
How does RBC Life Sciences, Inc. adapt to changing consumer preferences?
RBC Life Sciences, Inc. adapts to changing consumer preferences by monitoring market trends and investing in product innovation. The company focuses on developing new formulations and products that cater to evolving consumer needs and preferences. This includes incorporating natural and organic ingredients, addressing specific health concerns, and leveraging advancements in personalized nutrition. By staying attuned to consumer demand, RBC Life Sciences aims to maintain its competitiveness and relevance in the market.
How does RBC Life Sciences, Inc. manage supply chain and input cost risks?
RBC Life Sciences, Inc. manages supply chain and input cost risks by diversifying its supplier base and implementing cost-control measures. The company seeks to establish long-term relationships with reliable suppliers to ensure a stable supply of raw materials. It also monitors commodity prices and market conditions to anticipate potential cost increases. By proactively managing its supply chain and controlling costs, RBC Life Sciences aims to mitigate the impact of external factors on its profitability.
What are the key factors to evaluate for RBCL?
RBC Life Sciences, Inc. (RBCL) holds an AI score of 48/100 (low). Not financial advice.
How frequently does RBCL data refresh on this page?
RBCL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RBCL's recent stock price performance?
RBC Life Sciences, Inc. (RBCL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio including nutritional supplements and medical products. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited and less reliable than data for exchange-listed companies.
- AI analysis is pending and may provide additional insights in the future.